PortalPublikationenSuicide gene therapy for the treatment of high-grade glioma

Suicide gene therapy for the treatment of high-grade glioma

Standard

Suicide gene therapy for the treatment of high-grade glioma : past lessons, present trends, and future prospects. / Hossain, Jubayer A; Marchini, Antonio; Fehse, Boris; Bjerkvig, Rolf; Miletic, Hrvoje.

in: NEURO-ONCOL ADV, Jahrgang 2, Nr. 1, 10.07.2020, S. vdaa013.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Hossain, JA, Marchini, A, Fehse, B, Bjerkvig, R & Miletic, H 2020, 'Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects', NEURO-ONCOL ADV, Jg. 2, Nr. 1, S. vdaa013. https://doi.org/10.1093/noajnl/vdaa013

APA

Hossain, J. A., Marchini, A., Fehse, B., Bjerkvig, R., & Miletic, H. (2020). Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects. NEURO-ONCOL ADV, 2(1), vdaa013. https://doi.org/10.1093/noajnl/vdaa013

Vancouver

Hossain JA, Marchini A, Fehse B, Bjerkvig R, Miletic H. Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects. NEURO-ONCOL ADV. 2020 Jul 10;2(1):vdaa013. https://doi.org/10.1093/noajnl/vdaa013

Bibtex

@article{206a1d703aef48a3a424fd18af56f98d,
title = "Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects",
abstract = "Suicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising suicide gene therapy strategies in the clinic pointed toward a bleak future of this approach for the treatment of high-grade gliomas. Nevertheless, the development of new vectors and suicide genes, better prodrugs, more efficient delivery systems, and new combinatorial strategies represent active research areas that may eventually lead to better efficacy of suicide gene therapy. These trends are evident by the current increasing focus on suicide gene therapy for high-grade glioma treatment both in the laboratory and in the clinic. In this review, we give an overview of different suicide gene therapy approaches for glioma treatment and discuss clinical trials, delivery issues, and immune responses.",
author = "Hossain, {Jubayer A} and Antonio Marchini and Boris Fehse and Rolf Bjerkvig and Hrvoje Miletic",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.",
year = "2020",
month = jul,
day = "10",
doi = "10.1093/noajnl/vdaa013",
language = "English",
volume = "2",
pages = "vdaa013",
journal = "NEURO-ONCOL ADV",
issn = "2632-2498",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Suicide gene therapy for the treatment of high-grade glioma

T2 - past lessons, present trends, and future prospects

AU - Hossain, Jubayer A

AU - Marchini, Antonio

AU - Fehse, Boris

AU - Bjerkvig, Rolf

AU - Miletic, Hrvoje

N1 - © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

PY - 2020/7/10

Y1 - 2020/7/10

N2 - Suicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising suicide gene therapy strategies in the clinic pointed toward a bleak future of this approach for the treatment of high-grade gliomas. Nevertheless, the development of new vectors and suicide genes, better prodrugs, more efficient delivery systems, and new combinatorial strategies represent active research areas that may eventually lead to better efficacy of suicide gene therapy. These trends are evident by the current increasing focus on suicide gene therapy for high-grade glioma treatment both in the laboratory and in the clinic. In this review, we give an overview of different suicide gene therapy approaches for glioma treatment and discuss clinical trials, delivery issues, and immune responses.

AB - Suicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising suicide gene therapy strategies in the clinic pointed toward a bleak future of this approach for the treatment of high-grade gliomas. Nevertheless, the development of new vectors and suicide genes, better prodrugs, more efficient delivery systems, and new combinatorial strategies represent active research areas that may eventually lead to better efficacy of suicide gene therapy. These trends are evident by the current increasing focus on suicide gene therapy for high-grade glioma treatment both in the laboratory and in the clinic. In this review, we give an overview of different suicide gene therapy approaches for glioma treatment and discuss clinical trials, delivery issues, and immune responses.

U2 - 10.1093/noajnl/vdaa013

DO - 10.1093/noajnl/vdaa013

M3 - SCORING: Review article

C2 - 32642680

VL - 2

SP - vdaa013

JO - NEURO-ONCOL ADV

JF - NEURO-ONCOL ADV

SN - 2632-2498

IS - 1

ER -